PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$33.53
−0.15%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.1%
- EBIT
- —
- EPS
- +12.6%
- Free cash flow
- -13.7%
- Operating cash flow
- -14.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -21.5%
- EPS
- -14.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -19.2%
- EBIT
- -16.6%
- Net income
- -30.9%
- EPS
- -19.8%
- Free cash flow
- -13.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026